The Advisory Team at Enterin leverages its extensive scientific and regulatory expertise to guide the development and implementation of novel drug therapies that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. With a diverse group of scientific advisors, board members, and regulatory strategists, the team ensures that Enterin's groundbreaking treatments meet rigorous scientific and regulatory standards while advancing innovative research and clinical strategies.
Alan Moses
Scientific Advisory Board Memb...
Alexander Fleming
Scientific Advisor
Chris Dobson
Scientific Advisor
Hilde Williams
Senior Regulatory Advisor, Reg...
Linda Greensmith
Scientific Advisor
Michael Camilleri
Scientific Advisor
Michael Zemel
Scientific Advisory Board Memb...
Patrik Brundin
Scientific Advisory Board Memb...
Robert A. Hauser
Scientific Advisory Board Memb...
Wolfgang Kunze
Scientific Advisor
View all